EMA Recommends 104 Human Medicines in 2025 as EMANS 2028 and ESMP Go Operational

The European Medicines Agency's 2025 annual report sets a measurable baseline for EU market access planning: 104 human medicine recommendations, 38 involving new active substances never previously authorised in the EU, and the full operationalisation of two strategic frameworks that will reshape how manufacturers and regulatory affairs teams engage with the agency through the decade.

For QA directors and regulatory leads tracking supply continuity obligations, the activation of the European Shortages Monitoring Platform (ESMP) in 2025 is the most operationally immediate development. The platform formalises the EU's real-time visibility into medicine availability, placing new documentation and reporting expectations on marketing authorisation holders. Compliance planning for 2026 should account for ESMP's data-submission requirements alongside existing 21 CFR Part 211-equivalent GMP obligations for facilities supplying the EU market.

On the veterinary side, EMA recorded its highest recommendation volume for a second consecutive year, 30 medicines, including 16 vaccines. Seven of those vaccines were authorised under exceptional circumstances to address animal health emergencies, a pathway that signals continued regulatory flexibility under defined crisis conditions. The 13 new active substances in the veterinary pipeline indicate sustained innovation pressure on manufacturing sites handling novel biological and chemical entities.

The formal launch of the EU Medicines Agencies Network Strategy (EMANS) to 2028 provides the strategic envelope within which EMA's scientific committees will operate. For plant heads and regulatory affairs leads, EMANS 2028 signals where agency resources and inspection priorities will concentrate: digitalisation, AI integration in regulatory review, and implementation of the revised EU pharmaceutical legislation. EMA's own report notes the agency moved from AI exploration to practical application in 2025, a shift that will increasingly affect submission formatting, data integrity expectations, and post-authorisation variation timelines.

Sixteen of the recommended human medicines addressed rare diseases, reflecting the continued influence of the EU Orphan Regulation, now in its 25th year, on development and authorisation pathways. Three positive opinions were issued for medicines intended for use outside the EU, consistent with EMA's global public health mandate under Article 58 procedures.

The agency's full statistical breakdown, including detailed activity data relevant to GMP inspection frequency and scientific committee workloads, is scheduled for publication in the annual activity report before 1 July 2026, the more granular reference point for compliance benchmarking.

Source: European Medicines Agency via ema.europa.eu, 11 June 2026.